Skip to main content
. 2019 Jan 10;137(4):358–362. doi: 10.1001/jamaophthalmol.2018.6395

Figure. Prices of Adalimumab, Ranibizumab, and Aflibercept in the United States and Australia From 2013 to 2017.

Figure.

Drug prices are from the Centers for Medicare & Medicaid Services’ US Medicare Part B Drug and Biological Average Sales Price Index quarterly payment files and the Australian government’s Pharmaceutical Benefits Scheme. Decreasing prices were observed in Australia, whereas US prices increased or remained relatively stable for adalimumab, ranibizumab, and aflibercept. All prices are expressed in 2017 US dollars.